Tags : BerGenBio

COVID-19 Pharma

Bergenbio’s Bemcentinib Selected to be Fast-Tracked Under UK’s ACCORD Program

Shots: Bemcentinib has been selected as the first potential treatment to be fast-tracked under UK’s P-II ACCORD program that rapidly evaluates bemcentinib’s effectiveness in hospitalized UK NHS patients with COVID-19 The study will commence testing of bemcentinib vs SOC in 120 patients across 6 UK NHS hospital trusts with its anticipated results within few months. […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (October 21-25, 2019)

1. Urology San Antonio Collaborates with Anixa Biosciences on Ccheck Prostate Cancer Study Published: Oct 25, 2019 | Tags: Urology San Antonio, Collaborates, Anixa Biosciences, Ccheck, Prostate Cancer Study 2. NHS England Signs an Agreement with Vertex to Access All Licensed Cystic Fibrosis Therapies Published: Oct 24, 2019 | Tags: NHS England, Signs, Agreement, Vertex, Access, Licensed, […]Read More

Regulatory

BerGenBio’s Bemcentinib Receives the US FDA’s Fast Track Designation for

Shots: The US FDA has approved FT designation for Bemcentinib to treat elderly patients with acute myeloid leukemia (AML) whose disease has relapsed The FDA’s Fast Track designation facilitates the development and expedite the review of therapy to treat serious conditions and fill an unmet medical need Bemcentinib (BGB324) is a first-in-class selective AXL inhibitor, […]Read More